INM: financial statements from SEC — TradeAlmanac

INM

InMed Pharmaceuticals Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Revenue	—	820,188	1m	1m	1m	1m
Cost of revenue	—	635,994	716,962	1m	650,813	771,225
Gross profit	—	184,194	403,159	175,625	460,894	493,413
Research and development	1m	630,636	581,612	909,653	895,176	700,145
Selling, general and administrative	2m	2m	2m	1m	2m	1m
Operating expenses	3m	2m	2m	2m	3m	2m
Pre-tax income	−3m	−2m	−2m	−2m	−3m	−2m
Net income	−3m	−2m	−2m	−2m	−3m	−2m
Earnings per share	−0.73	−0.51	−0.44	−1.94	−3.64	−2.71
Earnings per share, diluted	−0.73	−0.51	−0.44	−1.94	−3.64	−2.71
Weighted average shares	4m	4m	4m	1m	706,546	620,127
Weighted average shares, diluted	4m	4m	4m	1m	706,546	620,127

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	5m	7m	9m	11m	5m	3m	6m	7m
Short-term investments	41,625	42,675

Cash flow

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Operating cash flow	—	—	−2m	—	—	−2m
Depreciation and amortisation	51,707	53,201	53,202	52,306

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)